What are extra pyramidal symptoms (EPS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Extrapyramidal Symptoms (EPS)

Extrapyramidal symptoms (EPS) are a group of movement disorders that occur as side effects of medications that block dopamine receptors, particularly antipsychotics, and are characterized by involuntary movements or muscle rigidity affecting various body parts. 1

Types of Extrapyramidal Symptoms

1. Acute Dystonia

  • Involves sudden spastic contractions of distinct muscle groups, often affecting the neck (torticollis), eyes (oculogyric crisis), or torso 1
  • Typically occurs during the initial phases of treatment, usually within 3-5 days after starting antipsychotics or increasing the dosage 2
  • Risk factors include young age, male gender, and use of high-potency antipsychotic agents 1
  • Can be extremely distressing and potentially life-threatening in cases of laryngospasm 1
  • Usually responds well to anticholinergic or antihistaminic medications 1, 3

2. Drug-Induced Parkinsonism

  • Presents with symptoms resembling Parkinson's disease, including:
    • Bradykinesia (slowed movements)
    • Tremors
    • Rigidity 1
  • Generally appears within the first three months of treatment 2
  • Can be difficult to differentiate from negative symptoms of schizophrenia or catatonia 1
  • Treated with anticholinergic agents, amantadine, or by reducing the antipsychotic dose 1, 2

3. Akathisia

  • Characterized by a subjective sense of severe restlessness and objective signs of motor restlessness 1
  • Frequently manifests as pacing, inability to sit still, or physical agitation 1
  • Commonly seen in patients treated with antipsychotics 1
  • Often misinterpreted as psychotic agitation or anxiety 1
  • A common reason for medication noncompliance 1
  • Difficult to treat; approaches include lowering antipsychotic dose, β-blockers, or benzodiazepines 1, 2

4. Tardive Dyskinesia

  • Characterized by involuntary, repetitive movements, typically of the face and mouth 4
  • Develops with long-term use of antipsychotics 4
  • Can be permanent even after medication discontinuation 5
  • Treatment options include VMAT2 inhibitors like valbenazine 6

Medications Associated with EPS

  • High-potency conventional antipsychotics (e.g., haloperidol) have the highest risk 1
  • Low-potency conventional antipsychotics (e.g., chlorpromazine) have lower EPS risk but more anticholinergic side effects 1
  • Atypical antipsychotics have lower but variable EPS risk (risperidone highest, clozapine and quetiapine lowest) 5
  • Non-antipsychotic medications that can cause EPS include certain antiemetics, antidepressants, lithium, and some anticonvulsants 7

Management of EPS

Acute Dystonia

  • Immediate treatment with anticholinergic medications such as intramuscular benztropine 1-2 mg or diphenhydramine 25-50 mg 3
  • Consider prophylactic anticholinergic agents for high-risk patients or those with history of dystonic reactions 3

Drug-Induced Parkinsonism

  • Reduce antipsychotic dose if clinically feasible 2
  • Add anticholinergic agent or amantadine 1
  • Consider switching to a lower-potency agent or atypical antipsychotic 2

Akathisia

  • Reduce antipsychotic dose if possible 1
  • Add β-blockers (especially propranolol or metoprolol) 2
  • Benzodiazepines may provide relief 1
  • Anticholinergic agents are less consistently helpful 1

Special Considerations

  • Children and adolescents may be at higher risk for EPS than adults 1
  • Monitoring for EPS is particularly important in youth due to limited studies in this population 1
  • Some movement disorders may be misdiagnosed as EPS, including those associated with hepatic encephalopathy 1
  • The term "EPS" has been criticized for lack of clinical, anatomical, and physiologic precision, with some experts suggesting more specific phenomenological descriptors 8

Prevention Strategies

  • Use the lowest effective dose of antipsychotic medication 2
  • Consider atypical antipsychotics with lower EPS risk when appropriate 5
  • Monitor patients closely, especially during initial treatment or dose increases 1
  • Prophylactic anticholinergic agents may be considered for high-risk patients, though long-term prophylaxis remains controversial 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Management of acute extrapyramidal effects induced by antipsychotic drugs.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1997

Guideline

Treatment for Acute Dystonic Reactions Caused by Haloperidol

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

EPS profiles: the atypical antipsychotics are not all the same.

Journal of psychiatric practice, 2007

Research

Extrapyramidal System/Symptoms/Signs Should Be Retired.

Neurology. Clinical practice, 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.